ライフサイエンスコーパス: cholinesterase inhibitor

1 Discontinuation vs continuation of cholinesterase inhibitor.

2 and were treated for at least 1 month with a cholinesterase inhibitor.

3 orted by an improvement of these symptoms by cholinesterase inhibitors.

4 detection of organophosphates or exposure to cholinesterase inhibitors.

5 itiated memantine, 1820 (11.2%) discontinued cholinesterase inhibitors.

6 ly accessible both for the substrate and for cholinesterase inhibitors.

7 rase system, and achieve effective dual FAAH/cholinesterase inhibitors.

8 r is as a promising new tool for analysis of cholinesterase inhibitors.

9 in locomotion behavior and responsiveness to cholinesterase inhibitors.

10 onsidered, concentrating upon studies of the cholinesterase inhibitors.

11 was no difference in efficacy among various cholinesterase inhibitors.

12 ntine or when to co-prescribe memantine with cholinesterase inhibitors.

13 1.52), cognitive stimulation combined with a cholinesterase inhibitor (-11.39, -18.38 to -3.93), mass

14 ong 82 patients with DLB and AD treated with cholinesterase inhibitors, 15% (n=12) showed symptomatic

15 f 1806 beneficiaries (2.8%) who discontinued cholinesterase inhibitors (3.4 per 100 person-years) and

16 lzheimer's dementia is commonly treated with cholinesterase inhibitors [4-7]; however, these are mode

17 oman-6-ol (CR-6) with that of the lipophilic cholinesterase inhibitor 6-chlorotacrine results in comp

18 vention patients were more likely to receive cholinesterase inhibitors (79.8% vs 55.1%; P = .002) and

19 organophosphorus compounds (OPs) are potent cholinesterase inhibitors, accounting for their use as i

20 We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline

21 We show that a brief treatment with the cholinesterase inhibitor aldicarb induces a form of pres

22 a systematic screening of the effect of the cholinesterase inhibitor aldicarb on the rate of pharyng

23 Pharmacological assays using the cholinesterase inhibitor aldicarb suggest that VAs and G

24 have an exaggerated paralytic response to a cholinesterase inhibitor, aldicarb.

25 chotic drugs alone (1.33, 1.24 to 1.43), and cholinesterase inhibitors alone (1.17, 1.10 to 1.24).

26 ures for different treatment periods: use of cholinesterase inhibitors alone, antipsychotic drugs alo

27 chotic drugs, antipsychotic drugs alone, and cholinesterase inhibitors alone, respectively.

28 tter addressed by multifunctional drugs than cholinesterase inhibitors alone.

29 Physostigmine (a centrally active cholinesterase inhibitor) also dose-dependently inhibite

30 d to determine the effects of galantamine, a cholinesterase inhibitor and a nicotinic allosteric pote

31 cluding a phenserine analogue as a potential cholinesterase inhibitor and constrained tryptamine deri

32 y measured the effects of treatment with the cholinesterase inhibitor and nicotinic receptor modulato

33 mal limb muscles, response to treatment with cholinesterase inhibitors and 3,4-diaminopyridine, and t

34 er of direct acting muscarinic agonists, two cholinesterase inhibitors and a putative m1 agonist/musc

35 ollowed by treatment with the combination of cholinesterase inhibitors and antipsychotic drugs (1.35,

36 1 (8.98 to 9.86) for use of a combination of cholinesterase inhibitors and antipsychotic drugs, antip

37 ipsychotic drugs alone, and a combination of cholinesterase inhibitors and antipsychotic drugs, compa

38 n the risk of falls and fractures and use of cholinesterase inhibitors and antipsychotic drugs.

39 studies demonstrated available drugs such as cholinesterase inhibitors and ChAT inducers increased th

40 Cholinesterase inhibitors and corticosteroids have been

41 Cholinesterase inhibitors and memantine do not have regu

42 for randomised, placebo-controlled trials on cholinesterase inhibitors and memantine in patients with

43 sess the evidence for efficacy and safety of cholinesterase inhibitors and memantine in vascular deme

44 Cholinesterase inhibitors and memantine may benefit pers

45 Cholinesterase inhibitors and memantine produce small be

46 Cholinesterase inhibitors and memantine slightly reduced

47 Cognitive enhancing drugs, such as cholinesterase inhibitors and methylphenidate, are used

48 ortant implications for the long-term use of cholinesterase inhibitors and other cholinomimetics in t

49 Evidence regarding the benefits of cholinesterase inhibitors and other therapeutic options

50 ning the interaction between carbamate-based cholinesterase inhibitors and their enzyme target.

51 r exploration such as escitalopram, lithium, cholinesterase inhibitors and vitamin D.

52 preservation of the cholinergic system (via cholinesterase inhibitors) and hippocampal neurons (via

53 erapy, cognitive stimulation combined with a cholinesterase inhibitor, and cognitive stimulation comb

54 Antipsychotics, cholinesterase inhibitors, and alpha-2 agonists are the

55 Short-term treatment with a cholinesterase inhibitor appears to enhance the activity

56 cotinic cholinergic agonists are used, or if cholinesterase inhibitors are combined with other agents

57 Cholinesterase inhibitors are commonly used to improve c

58 results from randomized controlled trials of cholinesterase inhibitors are conflicting.

59 More effective treatments than cholinesterase inhibitors are needed for Alzheimer's dis

60 erate clinically detected Alzheimer disease, cholinesterase inhibitors are somewhat effective in slow

61 Cholinesterase inhibitors are the primary treatment for

62 While cholinesterase inhibitors are used as drug treatments fo

63 , and fewer than 20% of patients stop taking cholinesterase inhibitors because of side effects.

64 , diarrhoea, and insomnia) occurred with the cholinesterase inhibitors, but not with memantine.

65 ifos and diazinon are bioactivated to potent cholinesterase inhibitors by cytochrome P-450 systems.

66 results indicate that one mechanism by which cholinesterase inhibitors can improve memory is by enhan

67 Phenserine, a recently developed cholinesterase inhibitor (ChEI), has been reported to re

68 Cholinesterase inhibitors (ChEIs) are specific Alzheimer

69 Cholinesterase inhibitors (ChEIs) may be effective treat

70 nd visual) were also affected in MCI and (2) cholinesterase inhibitors (ChEIs), one of the therapies

71 Therefore, use of a cholinesterase inhibitor (ChI) might improve cognitive f

72 Administration of a central cholinesterase inhibitor (ChI) partially restored the su

73 Cholinesterase inhibitor (ChI) therapy for mixed dementi

74 Prescription records of cholinesterase inhibitors confirmed the diagnosis of maj

75 In persons with MCI, cholinesterase inhibitors did not reduce dementia risk (

76 while neostigmine (a peripherally restricted cholinesterase inhibitor) did not.

77 he brains of healthy human subjects with the cholinesterase inhibitor donepezil (trade name: Aricept)

78 zed by fusing the pharmacophoric features of cholinesterase inhibitor donepezil and diarylthiazole as

79 found that cholinergic enhancement with the cholinesterase inhibitor donepezil improved target detec

80 The cholinesterase inhibitor donepezil was administered to n

81 The cholinesterase inhibitor, donepezil (Aricept), reverses

82 Cholinesterase inhibitor drugs improve cognition and neu

83 ch might help explain the limited success of cholinesterase inhibitor drugs in treating memory impair

84 In contrast, a cholinesterase inhibitor, eserine, although significantl

85 Stable use of cholinesterase inhibitors, estrogen, low-dose aspirin, a

86 um samples from individuals asymptomatic for cholinesterase inhibitor exposure were analyzed using th

87 euptake inhibitors for psychiatric symptoms, cholinesterase inhibitors for cognition).

88 Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-m

89 magnetic scavenging technique for extracting cholinesterase inhibitors from aqueous matrixes using bi

90 r a psychopharmacological challenge with the cholinesterase inhibitor galantamine (Reminyl).

91 trials of memantine in patients receiving a cholinesterase inhibitor have been performed.

92 These results indicate that cholinesterase inhibitors have a modest beneficial impac

93 PSP, but trials of cholinergic agonists and cholinesterase inhibitors have failed to show improvemen

94 The combination of the scaffolds of the cholinesterase inhibitor huprine Y and the antioxidant c

95 reatment typically includes symptomatic oral cholinesterase inhibitors, immunosuppression, and immuno

96 Cholinesterase inhibitors improve attention, as well as

97 Cholinesterase inhibitors improve cognitive outcomes in

98 ompared with placebo, patients randomized to cholinesterase inhibitors improved 0.1 SDs on ADL scales

99 ompared with placebo, patients randomized to cholinesterase inhibitors improved 1.72 points on the NP

100 treatment effects associated with the use of cholinesterase inhibitors in these populations.

101 cal symptomatic cholinergic therapy based on cholinesterase inhibitors is judiciously discussed for i

102 Treatment with cholinesterase inhibitors is well tolerated by most pati

103 dults with moderate to severe CATD receiving cholinesterase inhibitors, low- to insufficient-strength

104 ver, a combination of an M2 antagonist and a cholinesterase inhibitor may reach the maximal disease-m

105 h cognitive and behavioral disturbances, and cholinesterase inhibitors may improve behavior in Alzhei

106 Our findings suggest that treatment with cholinesterase inhibitors may improve muscle function in

107 Cholinesterase inhibitors may improve symptoms of dement

108 Alzheimer disease can be treated with cholinesterase inhibitors, memantine, and antiamyloid im

109 The cholinesterase inhibitor methyl paraoxon significantly d

110 Six to 12 months of treatment with cholinesterase inhibitors modestly slows the decline of

111 olinergic stimulation with pyridostigmine, a cholinesterase inhibitor, modulates heart and spleen imm

112 Known adverse events of cholinesterase inhibitors (nausea, vomiting, anorexia) w

113 with NAC in combination with the peripheral cholinesterase inhibitor neostigmine showed prolonged su

114 In the presence of the cholinesterase inhibitor neostigmine, EFS led to an addi

115 ceptor (mAChR) agonist, oxotremorine, or the cholinesterase inhibitor, neostigmine (NEOS), in the rRP

116 ny patients' preference to take memantine or cholinesterase inhibitors off-label rather than particip

117 te administration of rivastigmine, a central cholinesterase inhibitor, on patterns of brain activatio

118 Central Register and/or by prescription of a cholinesterase inhibitor or memantine hydrochloride from

119 cision to initiate a trial of therapy with a cholinesterase inhibitor or memantine on individualized

120 Concomitant treatment with cholinesterase inhibitors or memantine was permitted.

121 The effect of cholinesterase inhibitors or other treatments on persons

122 from our laboratory have shown that a novel cholinesterase inhibitor, phenserine, reduces betaAPP le

123 However, the administration of neither the cholinesterase inhibitor physostigmine nor the benzodiaz

124 We studied the effect of the cholinesterase inhibitor physostigmine on subcomponents

125 ned ACh elevation through application of the cholinesterase inhibitor physostigmine suppressed glutam

126 ith age, and attenuation by the nonselective cholinesterase inhibitor physostigmine, but no attenuati

127 artially susceptible to improvement with the cholinesterase inhibitor physostigmine.

128 Cholinesterase inhibitors positively affect cognition in

129 Cholinesterase inhibitors produce small improvements in

130 dence suggested that, compared with placebo, cholinesterase inhibitors produced small average improve

131 rior administration of muscarinic agonist or cholinesterase inhibitor) produced robust but transient

132 ncement of cholinergic neurotransmission via cholinesterase inhibitors represents the main available

133 Donepezil, a cholinesterase inhibitor, restored performance in animal

134 The cholinesterase inhibitors rivastigmine, donepezil, and m

135 Whether a cholinesterase inhibitor should be used as augmentation

136 rophosphate (DCP), a model organophosphorous cholinesterase inhibitor simulant.

137 ly reduced short-term cognitive decline, and cholinesterase inhibitors slightly reduced reported func

138 The cholinesterase inhibitors, tacrine and physostigmine, an

139 Unlike other cholinesterase inhibitors tested, rivastigmine inhibited

140 t dimethoxybenzilidene anabaseine (DMXB) and cholinesterase inhibitor tetrahydroaminoacridine (THA) w

141 We tested the premise that cholinesterase inhibitor therapy should target butyrylch

142 vides evidence for the long-term efficacy of cholinesterase inhibitor therapy suggesting a disease-mo

143 ia responds poorly to nonpharmacological and cholinesterase inhibitor therapy, and although corticost

144 of 91 participants, all receiving background cholinesterase inhibitor therapy, were randomized 1:1 be

145 The use of cholinesterase inhibitors to correct the cholinergic def

146 ddition, we need to know when to switch from cholinesterase inhibitors to memantine or when to co-pre

147 ehavioural symptoms, which is often added to cholinesterase inhibitors to potentiate their effect and

148 in injection, we administered neostigmine, a cholinesterase inhibitor, to artificially raise ACh.

149 es that provided a diagnosis, treatment with cholinesterase inhibitor together with physical and occu

150 blocking drugs and encapsulates them, making cholinesterase inhibitors unnecessary.

151 In this study, discontinuing cholinesterase inhibitors upon memantine initiation was

152 Galantamine, a cholinesterase inhibitor used in Alzheimer's disease, si

153 f major neurocognitive disorders; all use of cholinesterase inhibitors was reviewed by experts.

154 Rivastigmine, a cholinesterase inhibitor, was tested in a group of clini

155 effects of metrifonate, a second generation cholinesterase inhibitor, were examined on CA1 pyramidal

156 Discontinuing cholinesterase inhibitors when initiating memantine in p

157 -inflammatory therapy, immune-modulators and cholinesterase inhibitors which could lead to new therap

158 ucted to assess the impact of galantamine, a cholinesterase inhibitor with nicotinic-receptor-modulat